Department of Psychiatry & Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA Group Health Research Institute, Group Health, Seattle, WA, USA Alcohol and Drug Abuse Institute, University of Washington School of Medicine, Seattle, WA, USA Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Pain. 2010 May;149(2):345-353. doi: 10.1016/j.pain.2010.02.037. Epub 2010 Mar 23.
The value of chronic opioid therapy (COT) for chronic non-cancer pain (CNCP) patients is determined by a balance of poorly understood benefits and harms. Traditionally, this balance has been framed as the potential for improved pain control versus risks of iatrogenic addiction, drug diversion, and aberrant drug-related behaviors. These potential harms are typically defined from the providers' perspective. This paper seeks to clarify difficulties with the long-term use of opioids for CNCP from the patients' perspective. We used the Prescribed Opioids Difficulties Scale (PODS) to assess current problems and concerns attributed to opioid use by 1144 adults receiving COT. Subjects were grouped into low (56.9%), medium (25.6%) and high (17.5%) PODS scorers. Among patients with high PODS scores, 64% were clinically depressed and 78% experienced high levels of pain-related interference with activities, compared to 28% depressed and 60% with high interference with activities among those with low PODS scores. High levels of opioid-related problems and concerns were not explained by differences in pain intensity or persistence. Patients with medium to high PODS scores were often concerned about their ability to control their use of opioid medications, but prior substance abuse diagnoses and receiving excess days supply of opioids were much less common in these patients than depression and pain-related interference with activities. These results suggest two types of potential harm from COT attributed by CNCP patients to opioids: psychosocial problems that are distinct from poor pain control and opioid control concerns that are distinct from opioid misuse or addiction.
慢性阿片类药物治疗(COT)对慢性非癌性疼痛(CNCP)患者的价值取决于益处和危害的平衡,而这种平衡目前还难以理解。传统上,这种平衡被定义为改善疼痛控制的潜力与医源性成瘾、药物滥用和异常药物相关行为的风险之间的平衡。这些潜在的危害通常是从提供者的角度来定义的。本文旨在从患者的角度阐明长期使用阿片类药物治疗 CNCP 的困难。我们使用处方阿片类药物困难量表(PODS)评估了 1144 名接受 COT 的成年人目前与阿片类药物使用相关的问题和担忧。研究对象被分为低(56.9%)、中(25.6%)和高(17.5%)PODS 评分组。在 PODS 评分较高的患者中,64%的患者有临床抑郁,78%的患者疼痛相关活动受限程度较高,而 PODS 评分较低的患者中,28%的患者有抑郁,60%的患者疼痛相关活动受限程度较高。高水平的阿片类药物相关问题和担忧不能用疼痛强度或持续性的差异来解释。中等到高水平 PODS 评分的患者通常担心自己控制阿片类药物使用的能力,但与抑郁和疼痛相关活动受限相比,这些患者中先前的物质滥用诊断和过量的阿片类药物供应天数要少得多。这些结果表明,CNCP 患者归因于阿片类药物的 COT 有两种潜在危害:与疼痛控制不佳不同的心理社会问题,以及与阿片类药物滥用或成瘾不同的阿片类药物控制问题。